Literature DB >> 28556500

Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of anti-TNF-α therapy on sleep problems: A polisomnographic study.

Gulsah Karatas1, Ajda Bal2, Melike Yuceege3, Hikmet Firat3, Eda Gurcay2, Sadik Ardic3, Fatma Aytul Cakci2.   

Abstract

INTRODUCTION: This study was conducted to investigate the relationship between sleep quality (SQ) and disease activity (DA) in patients with ankylosing spondylitis (AS) and to evaluate the response to anti-tumor necrosis factor α (anti-TNF-α) therapy on sleep disorders.
MATERIALS AND METHODS: A total of 34 patients who met the modified New York classification criteria for AS were included in this prospective study. Patients were divided into two groups as follows: Group I (n = 15) with high DA and receiving anti-TNF-α therapy, and Group II (n = 19) in remission. DA was assessed by the Bath AS Disease Activity Index. Pittsburgh Sleep Quality Index (PSQI) and polysomnography (PSG) were used to determine disorders and patterns of sleep, respectively, in both groups at baseline as well as at the third month of anti-TNF-α therapy in Group I.
RESULTS: Baseline evaluation revealed impaired SQ in 57.9% of all patients. PSG demonstrated obstructive sleep apnea syndrome, snoring and periodic leg movements in 73.7%, 74.4% and 26.3% of patients, respectively. Prior to anti-TNF-α therapy, PSQI and snoring score were significantly higher in Group I (P = 0.0001, P = 0.012, respectively). Although there was a significant reduction in PSQI scores in Group I (P = 0.005) at the third month of anti-TNF-α therapy, no change was observed in PSG parameters (P > 0.05).
CONCLUSION: Sleep disorders increase in AS, particularly in patients with high DA. Anti-TNF-α therapy has improved SQ without any improvement in PSG. Therefore, it may be concluded that PSG parameters might be more associated with disease pathogenesis rather than DA in patients with AS.
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  ankylosing spondylitis; anti-TNF-α treatment; sleep disorders; sleep quality

Mesh:

Substances:

Year:  2017        PMID: 28556500     DOI: 10.1111/1756-185X.13102

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  3 in total

Review 1.  Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.

Authors:  Atul Deodhar; Lianne S Gensler; Marina Magrey; Jessica A Walsh; Adam Winseck; Daniel Grant; Philip J Mease
Journal:  Rheumatol Ther       Date:  2019-10-31

2.  Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset.

Authors:  Kathleen Tymms; Belinda E Butcher; Tracey L Sletten; Tegan Smith; Catherine O'Sullivan; Geoffrey Littlejohn; Ricky Sadler; Rebecca Tronnberg; Hedley Griffiths
Journal:  Clin Rheumatol       Date:  2021-11-26       Impact factor: 3.650

3.  Prevalence and factors related to sleep apnoea in ankylosing spondylitis.

Authors:  Adrian Wiginder; Carin Sahlin-Ingridsson; Mats Geijer; Anders Blomberg; Karl A Franklin; Helena Forsblad-d'Elia
Journal:  Clin Rheumatol       Date:  2021-09-28       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.